Related Experiment Video
Updated: Jan 8, 2026
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Harnessing mismatch repair deficiency for therapeutic targeting in cancers
Irem Yenidogan1, Uri Tabori1,2,3, Anirban Das1,2,3
1Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Introduction:
Mismatch-repair deficiency (MMRd) is a pan-cancer mechanism resulting in high tumor mutation and microsatellite burden, leading to remarkable therapeutic success using immune checkpoint inhibition (ICI). However, efficacy remains variable. Our goal is to review the existing and emerging literature that provide mechanistic insights on how MMRd diversely impacts the current landscape of cancer therapeutics.
Areas Covered:
We summarize the biological impact of MMRd, highlight how variable etiologies and different MMRd cancer-types have significant diversity in genomic and immune profiles, how this drives primary and acquired ICI-resistance, and highlight the clinical trial landscape and preclinical efforts to harness these distinct mechanistic vulnerabilities into new therapeutic strategies.
Expert Opinion:
MMRd is currently recognized a tumor-agnostic biomarker for ICI treatment. However, differences in the MMRd etio-biology impact the immune microenvironment, contributing to significant response heterogeneity. Some patients show dramatic response to neoadjuvant ICI monotherapy and don't even need surgery, while most will need biologically rational combination approaches. Additionally, MMRd-driven genomic instability can make this a 'moving target,' mandating an ongoing effort to track and adapt to MMRd-driven cancer and microenvironment evolution. The next decade will focus on how best to effectively tailor immune-directed therapies for different MMRd cancers.
Insights
Mismatch-repair deficiency (MMRd) drives tumor mutation and impacts immune checkpoint inhibition (ICI) therapy. Understanding MMRd's diverse effects is key to improving cancer treatment efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Mismatch-repair deficiency (MMRd) is a key mechanism in many cancers, leading to high tumor mutation burden.
- MMRd is a biomarker for immune checkpoint inhibition (ICI) therapy, but response rates vary significantly.
- The diverse biological underpinnings of MMRd contribute to heterogeneity in treatment outcomes.
Conclusions:
- MMRd is a tumor-agnostic biomarker, but its diverse nature necessitates personalized therapeutic approaches.
- Combination strategies are often required for optimal ICI efficacy in MMRd cancers.
- Future research should focus on adapting immune-directed therapies to specific MMRd cancer subtypes.
Related Concept Videos
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:36Mismatch Repair
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
02:31Homologous Recombination